Johnson & Johnson (NYSE:JNJ) VP Peter Fasolo Sells 20,000 Shares

Posted by Defense World Staff on Jul 28th, 2023

Johnson & Johnson (NYSE:JNJ – Get Free Report) VP Peter Fasolo sold 20,000 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Johnson & Johnson Stock Up 0.6 %

Shares of NYSE:JNJ opened at $173.71 on Friday. The stock’s 50-day moving average price is $161.14 and its 200-day moving average price is $161.22. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The stock has a market capitalization of $451.43 billion, a P/E ratio of 35.16, a price-to-earnings-growth ratio of 2.90 and a beta of 0.55. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same period last year, the firm earned $2.59 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.76 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.74%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. LCM Capital Management Inc increased its holdings in Johnson & Johnson by 0.7% during the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the period. Arbor Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 2.3% during the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after acquiring an additional 61 shares during the period. Sierra Capital LLC grew its holdings in shares of Johnson & Johnson by 0.6% during the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock worth $1,773,000 after acquiring an additional 61 shares during the period. MTM Investment Management LLC grew its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after acquiring an additional 61 shares during the period. Finally, Retirement Planning Group grew its holdings in shares of Johnson & Johnson by 1.8% during the 4th quarter. Retirement Planning Group now owns 3,437 shares of the company’s stock worth $607,000 after acquiring an additional 62 shares during the period. Hedge funds and other institutional investors own 67.57% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on JNJ shares. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, May 19th. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 price objective on shares of Johnson & Johnson in a research report on Friday, July 21st. Citigroup started coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective on the stock. Stifel Nicolaus increased their price objective on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Finally, Barclays increased their target price on Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research note on Monday. Eight equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $171.60.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.